Literature DB >> 7523031

Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.

D P Burns1, R C Desrosiers.   

Abstract

Studies in ungulate lentivirus systems clearly indicate that neutralization escape variants emerge over time in chronically infected animals. Studies in the EIAV system, in particular, have provided strong evidence that the humoral branch of the immune system is at least one selective force acting on an array of viral variants. In previous studies with the ungulate lentiviruses, molecularly cloned virus was never used, and plaque-purified virus was only sometimes used; the genetic determinants responsible for antigenic variation and immune selection were not determined. While molecular clones are available for HIV-1, immune selection studies have been hampered in this system by the fact that HIV-1 is infectious only for chimpanzees, which do not develop disease and are available in only limited numbers. Experiments on immune selection in humans are generally complicated by lack of knowledge on the time of infection and the genetic make-up of the infecting virus. Our studies on SIV immune selection summarized in this review provide definitive evidence that neutralization-resistant variants emerge in an individual during persistent infection by primate lentiviruses. By cloning viral envelope genes from rhesus monkeys over time and obtaining sequential serum samples from them, we have been able to study not only the evolution of envelope sequences but also the emergence of neutralization-resistant variants. Reciprocal neutralization studies were performed using parental and variant specific sera, and immune selection was demonstrated using molecularly cloned virus of defined sequence. During the course of persistent infection with SIV and HIV, there is clear selective pressure for change in discrete variable regions of envelope. The host neutralizing antibody response appears to be at least one of the selective forces driving sequence change in envelope since one result of the sequence variation is the emergence of neutralization escape mutants. This indicates that neutralizing antibodies do serve to limit HIV and SIV replication during the lengthy asymptomatic stage of infection. The coincidence of neutralization domains of HIV and/or SIV with variable regions V1, V2, V3, V4, V5, and V6 suggests a direct relationship between neutralization domains and the emergence of sequence variants. However, different selective forces may be responsible all or in part for driving sequence changes in some variable domains (summarized in Table 2). For example, alterations in cell and/or tissue tropism may be responsible at least in part for driving change in V3 and the cytotoxic T-lymphocyte response may be responsible for driving change in the signal peptide (V0; Henderson et al. 1992; Wei and Cresswell 1992).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523031     DOI: 10.1007/978-3-642-78536-8_11

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  31 in total

Review 1.  Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology.

Authors:  I M Rouzine; A Rodrigo; J M Coffin
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

5.  The Trojan exosome hypothesis.

Authors:  Stephen J Gould; Amy M Booth; James E K Hildreth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

Review 6.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

7.  Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors:  Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

8.  Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Authors:  T D Lockey; K S Slobod; T E Caver; S D'Costa; R J Owens; H M McClure; R W Compans; J L Hurwitz
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 9.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

10.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.